ENT/
Articles/
2509001419
  • Open Access
  • Research Article

HPV Genotype as a Predictor of Bevacizumab Treatment Response in Recurrent Respiratory Papillomatosis Patients

  • Xiaoyun Zhao 1, ‡,   
  • Ji Sun 2, ‡,   
  • Haiwen Yu 1, ‡,   
  • Rui Fang 1,   
  • Peijie He 1,   
  • Lei Cheng 1,   
  • Haitao Wu 1,   
  • Lan Lin 2,   
  • Jian Chen 1, 3, *,   
  • Chunsheng Wei 1, *,   
  • Jun Shao 1, *

Received: 11 Jun 2025 | Accepted: 20 Aug 2025 | Published: 16 Sep 2025

Abstract

Objective: : This study aimed to evaluate the clinical efficacy and safety of systemic bevacizumab in recurrent respiratory papillomatosis (RRP) and to explore the potential predictive value of human papillomavirus (HPV) genotype in this condition.

Methods: : A total of 34 patients with confirmed HPV6- or HPV11-associated RRP who received at least three doses of systemic bevacizumab were enrolled. Disease burden and clinical response were evaluated based on the number of interventions, Derkay scores, and voice-related quality of life (assessed using the Voice Handicap Index-30 for adults or the pediatric Voice Handicap Index for children) before and after treatment. Adverse events were documented and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Additionally, vascular endothelial growth factor A (VEGFA) expression in RRP tissues was measured by immunohistochemistry.

Results: : The overall response rate (ORR) was 70.59%. The frequency of surgical interventions was significantly reduced following treatment (median reduction from 2 to 0; P < 0.0001), and Derkay scores also showed a significant reduction (median reduction from 7.0 to 1.5; P < 0.0001). Adverse events were observed in 38.24% of patients, all of which were grade 1-2 and manageable. In juvenile-onset recurrent respiratory papillomatosis (JORRP), patients infected with HPV11 exhibited an ORR of 76.92%, with 57.58% achieving a ≥ 50% reduction in Derkay scores. In contrast, among patients infected with HPV6, the ORR was 57.14%, and only 45.83% demonstrated a ≥ 50% improvement in Derkay scores. Although these differences did not reach statistical significance, HPV11-positive patients with JORRP appeared to have a more favorable prognosis. Conversely, in adult-onset RRP (AORRP), patients with HPV11 infection had an ORR of 40% and a 16.67% rate of ≥ 50% Derkay score reduction, while those infected with HPV6 demonstrated an ORR of 88.89% and a 77.78% rate of significant Derkay score improvement. Similarly, a statistically significant reduction in surgical frequency before and after treatment was observed only in HPV11-positive JORRP patients and HPV6-positive AORRP patients. All groups of RRP showed VEGFA expression, but there was no significant difference.

Conclusion: : Systemic bevacizumab is effective and well-tolerated in both JORRP and AORRP. HPV genotype may influence therapeutic response and clinical outcomes in RRP patients receiving bevacizumab treatment. Specifically, HPV11-positive JORRP patients and HPV6-positive AORRP patients appear to derive greater benefit.

References 

  • 1.
    Benedict PA, Kravietz A, Achlatis E. . Prospective, multi-center study of the anatomic distribution of recurrent respiratory papillomatosis. Laryngoscope, 2022, 132(12): 2403–2411
  • 2.
    Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: a 2020 perspective. Laryngoscope Investig Otolaryngol, 2021, 6(2): 340–345
  • 3.
    Bedard MC, de Alarcon A, Kou YF. . HPV strain predicts severity of juvenile-onset recurrent respiratory papillomatosis with implications for disease screening. Cancers (Basel), 2021, 13(11): 2556
  • 4.
    Tjon Pian Gi RE, San Giorgi MR, Slagter-Menkema L. . Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Head Neck, 2015, 37(11): 1625–1632
  • 5.
    Nogueira RL, Küpper DS, do Bonfim CM. . HPV genotype is a prognosticator for recurrence of respiratory papillomatosis in children. Clin Otolaryngol, 2021, 46(1): 181–188
  • 6.
    Sibeko SR, Seedat RY. Adult-onset recurrent respiratory papillomatosis at a South African referral hospital. Indian J Otolaryngol Head Neck Surg, 2022, 74(Suppl 3): 5188–5193
  • 7.
    So RJ, Rayle C, Joo HH. . Systemic bevacizumab for recurrent respiratory papillomatosis: a single institution's experience. Laryngoscope, 2024, 134(7): 3253–3259
  • 8.
    Best SR, Bock JM, Fowler NB. . A consensus statement on the administration of systemic bevacizumab in patients with recurrent respiratory papillomatosis. Laryngoscope, 2024, 134(12): 5041–5046
  • 9.
    Ruiz R, Balamuth N, Javia LR, Zur KB. Systemic bevacizumab treatment for recurrent respiratory papillomatosis: long-term follow-up. Laryngoscope, 2022, 132(10): 2071–2075
  • 10.
    So RJ, Hidalgo Lopez JC, Ballestas SA. . Efficacy of systemic bevacizumab for recurrent respiratory papillomatosis with pulmonary involvement. Laryngoscope, 2024, 134(2): 577–581
  • 11.
    Zhao X, Wang J, Chen Q. . Systemic bevacizumab for treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol, 2024, 281(4): 1865–1875
  • 12.
    Norberg SM, Valdez J, Napier S. . PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. Lancet Respir Med, 2025, 13(4): 318–326
  • 13.
    Morrow MP, Gillespie E, Sylvester A. . DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. Nat Commun, 2025, 16(1): 1518
  • 14.
    So RJ, Hillel AT, Motz KM, Akst LM, Best SR. Factors associated with iatrogenic laryngeal injury in recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg, 2024, 170(4): 1091–1098
  • 15.
    Ovcinnikova O, Engelbrecht K, Verma M. . A systematic literature review of the epidemiology, clinical, economic and humanistic burden in recurrent respiratory papillomatosis. Respir Res, 2024, 25(1): 430
  • 16.
    Yamada S, Itoh T, Ikegami T. . Association between human papillomavirus particle production and the severity of recurrent respiratory papillomatosis. Sci Rep, 2023, 13(1): 5514
  • 17.
    San Giorgi MRM, Aaltonen LM, Rihkanen H. . Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope, 2017, 127(8): 1826–1831
  • 18.
    Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope, 2004, 114: 1–23
  • 19.
    Intakorn P, Sonsuwan N. Human papillomatosis genotyping and severity in patients with recurrent respiratory papillomatosis. J Med Assoc Thai, 2014, 97(6): S136–S141
  • 20.
    Li G, He L, Zhang E. . Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non-small cell lung cancer cells. Cancer Lett, 2011, 311(2): 160–170
  • 21.
    Huang B, Zhou Z, Liu J. . The role of monoamine oxidase A in HPV-16 E7-induced epithelial-mesenchymal transition and HIF-1α protein accumulation in non-small cell lung cancer cells. Int J Biol Sci, 2020, 16(14): 2692–2703
  • 22.
    Gáll T, Kis A, Fehér E, Gergely L, Szarka K. Virological failure of intralesional cidofovir therapy in recurrent respiratory papillomatosis is not associated with genetic or epigenetic changes of HPV11: complete genome comparison of sequential isolates. Antiviral Res, 2011, 92(2): 356–358
  • 23.
    Measso do Bonfim C, Simão Sobrinho J, Lacerda Nogueira R. . Differences in transcriptional activity of human papillomavirus type 6 molecular variants in recurrent respiratory papillomatosis. PLoS One, 2015, 10(7): e0132325
  • 24.
    Cisneros B, García-Aguirre I, Unzueta J. . Immune system modulation in aging: molecular mechanisms and therapeutic targets. Front Immunol, 2022, 13: 1059173
  • 25.
    Pacinella G, Ciaccio AM, Tuttolomondo A. Endothelial dysfunction and chronic inflammation: the cornerstones of vascular alterations in age-related diseases. Int J Mol Sci, 2022, 23(24): 15722
  • 26.
    Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res, 2007, 13(4): 1098–1106
  • 27.
    Wallin JJ, Bendell JC, Funke R. . Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun, 2016, 7: 12624
  • 28.
    Camus M, Tosolini M, Mlecnik B. . Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res, 2009, 69(6): 2685–2693
  • 29.
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res, 1999, 5(10): 2963–2970
Share this article:
Download PDF
DOI
10.15302/ENTD.2025.090004
Issue
Volume 1, Issue 1
How to Cite
Zhao, X.; Sun, J.; Yu, H.; Fang, R.; He, P.; Cheng, L.; Wu, H.; Lin, L.; Chen, J.; Wei, C.; Shao, J. HPV Genotype as a Predictor of Bevacizumab Treatment Response in Recurrent Respiratory Papillomatosis Patients. ENT Discovery 2025, 1 (1), 12–22. https://doi.org/10.15302/ENTD.2025.090004.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2025 by the authors.